(Q53654914)

English

Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

scientific article published on 28 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. (English)

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

A Canut

1

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

A Isla

2

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

C Betriu

3

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

A R Gascón

4

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

publication date

28 February 2012

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

European Journal of Clinical Microbiology & Infectious Diseases

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

31

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

9

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

2227-2235

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

https://scigraph.springernature.com/pub.10.1007/s10096-012-1560-7

0 references

Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Methicillin-resistant Staphylococcus aureus disease in three communities

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Clinical and molecular epidemiology of community-acquired, healthcare-associated and nosocomial methicillin-resistant Staphylococus aureus in Spain

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Management of methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Antimicrobial resistance in the UK and Ireland

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Continuous infusion of beta-lactams.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Pharmacodynamic optimization of beta-lactams in the patient care setting

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Pharmacokinetic studies of linezolid and teicoplanin in the critically ill.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

In vivo pharmacodynamics of a new oxazolidinone (linezolid)

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

In vivo pharmacodynamic activity of daptomycin

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

National guidelines for the judicious use of glycopeptides in Belgium.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance

1 reference

https://api.crossref.org/works/10.1007%2FS10096-012-1560-7

21 January 2018

Pharmacokinetic/pharmacodynamic analysis to optimize antibacterial treatments: prediction of efficacy by using Montecarlo simulation techniques

1 reference

https://pubmed.ncbi.nlm.nih.gov/22371294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Public health surveillance for methicillin-resistant Staphylococcus aureus: comparison of methods for classifying health care- and community-associated infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/22371294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A brief introduction to Monte Carlo simulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22371294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05

1 reference

https://pubmed.ncbi.nlm.nih.gov/22371294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for prevention, control and treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22371294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22371294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22371294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22371294

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10096-012-1560-7

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/22371294

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53654914&oldid=2144498074"